AR and metastatic prostate carcinoma: When we applied this CTC assay to a large cohort of patients with metastatic prostate cancer, we identified a distinct cluster C2 characterized by high expression of AR target genes, which was prognostic for OS independent of other variables including AR-V status, CRPC, and NEPC.